Press releases
- Charles River Laboratories Schedules Second-Quarter 2024 Earnings Release and Conference Call
- Charles River to Perform Plasmid Manufacturing for AAVantgarde
- Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute at University of Colorado Anschutz Medical Campus
- Charles River and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy
- Charles River Laboratories, in Collaboration With MatTek Corporation, Awarded Grant from the Foundation for Chemistry Research and Initiatives to Advance Research Alternatives
- Charles River Laboratories Expands Access to CRADL® Contract Vivarium Space in Somerville
- Charles River Laboratories Announces Development of Nonclinical Virtual Control Groups with Sanofi to Reduce the Use of Animals in Research
- Charles River Laboratories to Present at William Blair and Jefferies Conferences
- Charles River Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development
- Charles River Laboratories Announces First-Quarter 2024 Results
More ▼
Key statistics
On Monday, Charles River Laboratories International Inc (RV6:BER) closed at 205.10, -18.87% below its 52-week high of 252.80, set on Mar 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 200.50 |
---|---|
High | 206.80 |
Low | 200.40 |
Bid | 206.00 |
Offer | 212.50 |
Previous close | 199.55 |
Average volume | 1.71 |
---|---|
Shares outstanding | 51.51m |
Free float | 51.00m |
P/E (TTM) | 26.18 |
Market cap | 11.49bn USD |
EPS (TTM) | 8.52 USD |
Data delayed at least 15 minutes, as of Jul 22 2024 19:21 BST.
More ▼